Organon & Co. (OGN) Competitors $8.74 -0.26 (-2.89%) As of 05/20/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OGN vs. ROIV, RVMD, BBIO, BPMC, ELAN, LEGN, TGTX, TLX, VRNA, and LNTHShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Roivant Sciences Revolution Medicines BridgeBio Pharma Blueprint Medicines Elanco Animal Health Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus Organon & Co. (NYSE:OGN) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do analysts recommend OGN or ROIV? Organon & Co. currently has a consensus target price of $18.00, suggesting a potential upside of 105.95%. Roivant Sciences has a consensus target price of $17.50, suggesting a potential upside of 58.51%. Given Organon & Co.'s higher probable upside, research analysts clearly believe Organon & Co. is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, OGN or ROIV? Roivant Sciences has lower revenue, but higher earnings than Organon & Co.. Roivant Sciences is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.29B0.36$864M$2.883.03Roivant Sciences$122.59M64.26$4.35B-$0.15-73.60 Which has more risk and volatility, OGN or ROIV? Organon & Co. has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Is OGN or ROIV more profitable? Organon & Co. has a net margin of 13.49% compared to Roivant Sciences' net margin of -119.54%. Organon & Co.'s return on equity of 431.62% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.13.49% 431.62% 8.03% Roivant Sciences -119.54%-14.05%-12.81% Does the MarketBeat Community prefer OGN or ROIV? Roivant Sciences received 36 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 78.57% of users gave Roivant Sciences an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes1933.33% Underperform Votes3866.67% Roivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% Does the media favor OGN or ROIV? In the previous week, Roivant Sciences had 3 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for Roivant Sciences and 10 mentions for Organon & Co.. Roivant Sciences' average media sentiment score of 1.44 beat Organon & Co.'s score of 0.41 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of OGN or ROIV? 77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 2.0% of Organon & Co. shares are owned by company insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryRoivant Sciences beats Organon & Co. on 10 of the 18 factors compared between the two stocks. Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.27B$6.55B$5.43B$19.70BDividend Yield0.91%2.66%5.22%3.84%P/E Ratio2.629.1426.8335.13Price / Sales0.36255.60392.3534.12Price / Cash3.1265.8538.2517.51Price / Book-32.376.546.874.78Net Income$864M$143.51M$3.22B$1.02B7 Day Performance8.57%5.60%6.76%1.62%1 Month Performance-18.09%10.06%13.66%13.00%1 Year Performance-59.98%-0.86%18.27%5.59% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.7922 of 5 stars$8.74-2.9%$18.00+105.9%-59.8%$2.27B$6.29B2.6210,000Trending NewsROIVRoivant Sciences2.0151 of 5 stars$10.99+3.3%$17.50+59.2%-2.9%$7.84B$122.59M-73.26860Positive NewsRVMDRevolution Medicines4.4108 of 5 stars$41.88+3.6%$67.17+60.4%+1.1%$7.80B$742,000.00-11.67250Positive NewsBBIOBridgeBio Pharma4.6499 of 5 stars$35.68+4.4%$57.09+60.0%+14.2%$6.77B$127.42M-12.52400Positive NewsInsider TradeBPMCBlueprint Medicines1.8307 of 5 stars$100.31+3.2%$126.56+26.2%-1.2%$6.48B$562.12M-92.88640Positive NewsELANElanco Animal Health3.2726 of 5 stars$12.82+7.2%$15.00+17.0%-23.1%$6.36B$4.43B32.049,800Analyst ForecastGap UpLEGNLegend Biotech3.5838 of 5 stars$32.38+1.9%$78.82+143.4%-33.8%$5.95B$627.24M-34.081,070News CoverageAnalyst RevisionTGTXTG Therapeutics3.8401 of 5 stars$34.99+4.0%$40.80+16.6%+115.2%$5.56B$386.39M-349.87290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/AGap DownVRNAVerona Pharma1.8854 of 5 stars$67.53+6.6%$81.50+20.7%+484.7%$5.48B$118.54M-35.1730Positive NewsLNTHLantheus4.5048 of 5 stars$79.52-2.7%$132.67+66.8%-7.3%$5.45B$1.54B13.23700Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ROIV Alternatives RVMD Alternatives BBIO Alternatives BPMC Alternatives ELAN Alternatives LEGN Alternatives TGTX Alternatives TLX Alternatives VRNA Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGN Stock Free OGN Stock Alerts